Induction with lopinavir-based treatment followed by switch to nevirapine-based regimen versus non-nucleoside reverse transcriptase inhibitors-based treatment for first line antiretroviral therapy in HIV infected children three years and older

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Alvarez Uria, Gerardo ^a   Pakam, Raghavakalyan ^a   Naik, Praveen Kumar ^a   Midde, Manoranjan ^a  

^a Rural Development Trust Hospital   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; EFAVIRENZ; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HAZARD RATIO; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PROPENSITY SCORE; RETROSPECTIVE STUDY; RURAL AREA; SENSITIVITY ANALYSIS; VIRUS LOAD; ANTIVIRAL RESISTANCE; COMBINATION DRUG THERAPY; HIV INFECTIONS; INDUCTION CHEMOTHERAPY; PRESCHOOL CHILD; TREATMENT OUTCOME; VIROLOGY;

CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDUCTION CHEMOTHERAPY; LOPINAVIR; MALE; NEVIRAPINE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84907225926     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108063     Document Type: Article

References (34)

1. Kamya MR, Mayanja-Kizza H, Kambugu A, Bakeera-Kitaka S, Semitala F, et al. (2007) Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr 46: 187-193. doi:10.1097/QAI.0b013e31814278c0.
2. Sigaloff KCE, Calis JCJ, Geelen SP, van Vugt M, de Wit TFR (2011) HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review. Lancet Infect Dis 11: 769-779. doi:10.1016/S1473-3099(11)70141-4.
3. Dlamini JN, Hu Z, Ledwaba J, Morris L, Maldarelli FM, et al. (2011) Genotypic resistance at viral rebound among patients who received lopinavir/ritonavirbased or efavirenz-based first antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 58: 304-308. doi:10.1097/QAI.0b013e3182278c29.
4. Lockman S, Hughes M, Sawe F, Zheng Y, McIntyre J, et al. (2012) Nevirapineversus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. PLoS Med 9: e1001236. doi:10.1371/journal.pmed.1001236.
5. Violari A, Lindsey JC, Hughes MD, Mujuru HA, Barlow-Mosha L, et al. (2012) Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med 366: 2380-2389. doi:10.1056/NEJMoa1113249.
6. Palumbo P, Lindsey JC, Hughes MD, Cotton MF, Bobat R, et al. (2010) Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med 363: 1510-1520. doi:10.1056/NEJMoa1000931.
7. Jaspan HB, Berrisford AE, Boulle AM (2008) Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program. Pediatr Infect Dis J 27: 993-998. doi:10.1097/INF.0b013e31817acf7b.
8. Estripeaut D, Mosser J, Doherty M, Acosta W, Shah H, et al. (2013) Mortality and long-term virologic outcomes in children and infants treated with lopinavir/ritonavir. Pediatr Infect Dis J 32: e466-472. doi:10.1097/INF. 0b013e3182a09276.
9. Alvarez-Uria G, Naik PK, Pakam R, Midde M (2012) Early HIV viral load determination after initiating first-line antiretroviral therapy for indentifying patients with high risk of developing virological failure: data from a cohort study in a resource-limited setting. Trop Med Int Health 17: 1152-1155. Available: http://www.ncbi.nlm.nih.gov/pubmed/22487689. Accessed 2012 Sep 7.
10. Arpadi S, Shiau S, Strehlau R, Martens L, Patel F, et al. (2013) Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy. Arch Dis Child 98: 258-264. doi:10.1136/archdischild-2012-302633.
11. Office of The Registrar General & Census Commissioner, India (2011) Census of India.
12. Alvarez-Uria G, Midde M, Pakam R, Naik PK (2012) Gender differences, routes of transmission, socio-demographic characteristics and prevalence of HIV related infections of adults and children in an HIV cohort from a rural district of India. Infect Dis Rep 4: e19. doi:10.4081/idr.2012.e19.
13. Alvarez-Uria G, Midde M, Pakam R, Kannan S, Bachu L, et al. (2012) Factors Associated with Late Presentation of HIV and Estimation of Antiretroviral Treatment Need according to CD4 Lymphocyte Count in a Resource-Limited Setting: Data from an HIV Cohort Study in India. Interdiscip Perspect Infect Dis 2012: 293795. doi:10.1155/2012/293795.
14. Alvarez-Uria G, Midde M, Pakam R, Bachu L, Naik PK (2012) Effect of Formula Feeding and Breastfeeding on Child Growth, Infant Mortality, and HIV Transmission in Children Born to HIV-Infected Pregnant Women Who Received Triple Antiretroviral Therapy in a Resource-Limited Setting: Data from an HIV Cohort Study in India. ISRN Pediatr 2012: 763591. doi:10.5402/2012/763591.
15. National AIDS Control Organisation (2006) Guidelines for HIV Care and Treatment in Infants and Children. Available: http://www.nacoonline.org/NACO/About-NACO/Policy-Guidelines/Policies-Guidelines1/. Accessed 2013 Jul 31.
16. Sáez-Llorens X, Violari A, Deetz CO, Rode RA, Gomez P, et al. (2003) Fortyeight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J 22: 216-224. doi:10.1097/01.inf.0000055061.97567.34.
17. Ramos J (2009) Boosted protease inhibitors as a therapeutic option in the treatment of HIV-infected children. HIV Med 10: 536-547. doi:10.1111/j.1468-1293.2009.00728.x.
18. World Health Organization (2010) Antiretroviral therapy for HIV infection in infants and children: Towards universal access. Available: http://www.who.int/hiv/pub/paediatric/infants2010/en/index.html. Accessed 2011 Feb 10.
19. PENTA Steering Committee, Welch S, Sharland M, Lyall EGH, Tudor-Williams G, et al. (2009) PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med 10: 591-613. doi:10.1111/j.1468-1293.2009.00759.x.
20. World Health Organization (2013) Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Available: http://www.who.int/hiv/pub/guidelines/arv2013/en/index.html. Accessed 2013 Jul 20.
21. Gang IN, Sen K, Yun MS (2002) Caste, Ethnicity, and Poverty in Rural India. IZA.
22. Alvarez-Uria G, Midde M, Naik PK (2012) Socio-demographic risk factors associated with HIV infection in patients seeking medical advice in a rural hospital of India. J Public health Res 1: e14. doi:10.4081/jphr.2012.e14.
23. HIV Paediatric Prognostic Markers Collaborative Study, Boyd K, Dunn DT, Castro H, Gibb DM, et al. (2010) Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children. AIDS 24: 1213-1217. doi:10.1097/QAD. 0b013e3283389f41.
24. HIV Paediatric Prognostic Markers Collaborative Study (2006) Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children. AIDS 20: 1289-1294. doi:10.1097/01.aids.0000232237.20792.68.
25. www.hppmcs.org (n.d.). Available: http://www.hppmcs.org/. Accessed 2013 Aug 11.
26. Royston P (2009) Multiple imputation of missing values: Further update of ice, with an emphasis on categorical variables. Stata Journal 9: 466-477.
27. Ridgeway G, McCaffrey D, Morral A, Burgette L, Griffin BA (2013) Toolkit for Weighting and Analysis of Nonequivalent Groups: A tutorial for the twang package. R vignette RAND.
28. McCaffrey DF, Griffin BA, Almirall D, Slaughter ME, Ramchand R, et al. (2013) A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med 32: 3388-3414. doi:10.1002/sim.5753.
29. Hill J (2004) Reducing bias in treatment effect estimation in observational studies suffering from missing data. Available: http://academiccommons.columbia.edu/catalog/ac:129151. Accessed 2 July 2014.
30. Austin PC (2013) A tutorial on the use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med. doi:10.1002/sim.5984.
31. Violari A, Lindsey JC, Hughes MD, Mujuru HA, Barlow-Mosha L, et al. (2012) Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med 366: 2380-2389. doi:10.1056/NEJMoa1113249.
32. PENPACT-1 (PENTA 9/PACTG 390) Study Team, Babiker A, Castronee Green H, Compagnucci A, Fiscus S, et al. (2011) First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an openlabel, randomised phase 2/3 trial. Lancet Infect Dis 11: 273-283. doi:10.1016/S1473-3099(10)70313-3.
33. Kuhn L, Coovadia A, Strehlau R, Martens L, Hu C-C, et al. (2012) Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Lancet Infect Dis 12: 521-530. doi:10.1016/S1473-3099(12)70051-8.
34. UNITAID (n.d.) HIV/AIDS Diagnostics Technology Landscape 4th Edition. Available: http://www.unitaid.eu/images/marketdynamics/publications/UNITAID-HIV-Diagnostic-Landscape-4th-edition.pdf.